AbbVie, Thermo Fisher Scientific, Danaher, Vertex Pharmaceuticals, Cognizant Technology Solutions, Veeva Systems, and Cencora are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of publicly traded companies that research, develop and commercialize products based on biological processes—such as drugs, vaccines, gene therapies and diagnostic tools. Investors in these stocks gain exposure to the potential high growth (and risks) associated with scientific breakthroughs, clinical trial outcomes and regulatory approvals in the life-sciences industry. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.
AbbVie (ABBV)
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
Shares of NYSE ABBV traded up $2.34 during trading on Friday, hitting $184.02. 6,151,228 shares of the company traded hands, compared to its average volume of 6,247,870. The company has a quick ratio of 0.55, a current ratio of 0.66 and a debt-to-equity ratio of 17.94. The company has a 50-day moving average price of $191.30 and a 200-day moving average price of $186.97. The firm has a market capitalization of $325.06 billion, a P/E ratio of 76.68, a P/E/G ratio of 1.62 and a beta of 0.56. AbbVie has a 1 year low of $153.58 and a 1 year high of $218.66.
Read Our Latest Research Report on ABBV
Thermo Fisher Scientific (TMO)
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Shares of Thermo Fisher Scientific stock traded up $7.22 during trading on Friday, reaching $412.15. The company had a trading volume of 2,498,185 shares, compared to its average volume of 1,840,883. The company has a market cap of $155.58 billion, a price-to-earnings ratio of 24.93, a price-to-earnings-growth ratio of 2.99 and a beta of 0.82. Thermo Fisher Scientific has a fifty-two week low of $390.50 and a fifty-two week high of $627.88. The firm's fifty day moving average is $453.88 and its 200-day moving average is $510.15. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66.
Read Our Latest Research Report on TMO
Danaher (DHR)
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Shares of NYSE:DHR traded up $5.08 during trading hours on Friday, hitting $196.03. The stock had a trading volume of 3,868,501 shares, compared to its average volume of 3,454,106. The stock's fifty day simple moving average is $196.87 and its 200 day simple moving average is $217.47. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.40. The firm has a market capitalization of $140.29 billion, a price-to-earnings ratio of 37.13, a PEG ratio of 2.66 and a beta of 0.80. Danaher has a 1-year low of $171.00 and a 1-year high of $281.70.
Read Our Latest Research Report on DHR
Vertex Pharmaceuticals (VRTX)
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.
Shares of NASDAQ:VRTX traded up $4.27 during mid-day trading on Friday, hitting $438.65. The stock had a trading volume of 1,505,089 shares, compared to its average volume of 1,410,037. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.35 and a current ratio of 2.69. The company has a market cap of $112.64 billion, a PE ratio of -199.39, a P/E/G ratio of 2.11 and a beta of 0.51. Vertex Pharmaceuticals has a 12-month low of $377.85 and a 12-month high of $519.88. The company's 50 day moving average is $482.97 and its 200-day moving average is $464.44.
Read Our Latest Research Report on VRTX
Cognizant Technology Solutions (CTSH)
Cognizant Technology Solutions Corporation, a professional services company, provides consulting and technology, and outsourcing services in North America, Europe, and internationally. It operates through four segments: Financial Services, Health Sciences, Products and Resources, and Communications, Media and Technology.
Shares of Cognizant Technology Solutions stock traded up $0.08 during midday trading on Friday, reaching $81.44. 5,603,555 shares of the company's stock traded hands, compared to its average volume of 3,568,115. The company has a market cap of $40.28 billion, a price-to-earnings ratio of 18.06, a price-to-earnings-growth ratio of 2.11 and a beta of 0.93. Cognizant Technology Solutions has a 52 week low of $63.79 and a 52 week high of $90.82. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.09 and a current ratio of 2.09. The company's 50 day simple moving average is $75.00 and its 200 day simple moving average is $78.84.
Read Our Latest Research Report on CTSH
Veeva Systems (VEEV)
Veeva Systems Inc. provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.
NYSE VEEV traded up $0.88 during midday trading on Friday, hitting $242.48. The company had a trading volume of 1,743,658 shares, compared to its average volume of 1,102,501. The stock has a market cap of $39.45 billion, a price-to-earnings ratio of 59.87, a P/E/G ratio of 1.89 and a beta of 0.96. The firm has a fifty day simple moving average of $228.63 and a two-hundred day simple moving average of $226.29. Veeva Systems has a fifty-two week low of $170.25 and a fifty-two week high of $258.93.
Read Our Latest Research Report on VEEV
Cencora (COR)
Cencora, Inc. sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.
Shares of Cencora stock traded up $4.27 during trading on Friday, hitting $290.24. 1,355,556 shares of the company's stock traded hands, compared to its average volume of 1,544,753. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.54. The firm's fifty day moving average price is $279.10 and its 200 day moving average price is $255.16. Cencora has a twelve month low of $214.77 and a twelve month high of $309.35. The company has a market cap of $56.28 billion, a PE ratio of 41.29, a PEG ratio of 1.31 and a beta of 0.60.
Read Our Latest Research Report on COR
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider AbbVie, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.
While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
